| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Intracranial Aneurysm | 60 | 2025 | 382 | 7.880 |
Why?
|
| Stents | 47 | 2025 | 500 | 7.710 |
Why?
|
| Stroke | 45 | 2023 | 1219 | 5.510 |
Why?
|
| Thrombosis | 23 | 2023 | 207 | 4.670 |
Why?
|
| Brain Ischemia | 27 | 2023 | 420 | 4.430 |
Why?
|
| Thrombectomy | 30 | 2024 | 262 | 4.300 |
Why?
|
| Embolization, Therapeutic | 35 | 2024 | 335 | 3.800 |
Why?
|
| Endovascular Procedures | 32 | 2026 | 631 | 3.430 |
Why?
|
| Tomography, Optical Coherence | 17 | 2026 | 236 | 3.420 |
Why?
|
| Disease Models, Animal | 32 | 2025 | 2307 | 3.060 |
Why?
|
| Blood Vessel Prosthesis | 17 | 2021 | 215 | 2.220 |
Why?
|
| Infarction, Middle Cerebral Artery | 6 | 2019 | 91 | 2.020 |
Why?
|
| Intracranial Embolism | 4 | 2021 | 41 | 1.910 |
Why?
|
| Mechanical Thrombolysis | 6 | 2016 | 36 | 1.890 |
Why?
|
| Models, Anatomic | 10 | 2023 | 63 | 1.890 |
Why?
|
| Device Removal | 4 | 2020 | 64 | 1.750 |
Why?
|
| Cerebral Angiography | 28 | 2023 | 299 | 1.640 |
Why?
|
| Treatment Outcome | 63 | 2025 | 5811 | 1.490 |
Why?
|
| Magnetic Resonance Angiography | 7 | 2021 | 186 | 1.470 |
Why?
|
| Dogs | 17 | 2026 | 315 | 1.430 |
Why?
|
| Animals | 78 | 2026 | 21394 | 1.420 |
Why?
|
| Middle Cerebral Artery | 5 | 2023 | 51 | 1.380 |
Why?
|
| Cerebrovascular Disorders | 6 | 2026 | 83 | 1.280 |
Why?
|
| Peroxidase | 5 | 2023 | 70 | 1.210 |
Why?
|
| Cone-Beam Computed Tomography | 8 | 2017 | 71 | 1.180 |
Why?
|
| Rabbits | 23 | 2024 | 339 | 1.160 |
Why?
|
| Imaging, Three-Dimensional | 13 | 2026 | 300 | 1.160 |
Why?
|
| Humans | 130 | 2026 | 65498 | 1.120 |
Why?
|
| Angiography, Digital Subtraction | 17 | 2024 | 139 | 1.110 |
Why?
|
| Phantoms, Imaging | 6 | 2024 | 236 | 1.110 |
Why?
|
| Magnetic Resonance Imaging | 21 | 2024 | 2247 | 1.080 |
Why?
|
| Hemodynamics | 4 | 2020 | 252 | 0.990 |
Why?
|
| Swine | 14 | 2024 | 397 | 0.940 |
Why?
|
| Thromboembolism | 5 | 2024 | 74 | 0.930 |
Why?
|
| Brain | 8 | 2019 | 1611 | 0.890 |
Why?
|
| Biomechanical Phenomena | 4 | 2021 | 293 | 0.840 |
Why?
|
| Neurosurgical Procedures | 2 | 2023 | 105 | 0.830 |
Why?
|
| Catheters | 10 | 2022 | 76 | 0.780 |
Why?
|
| Subarachnoid Space | 2 | 2026 | 15 | 0.770 |
Why?
|
| Angiography | 11 | 2021 | 154 | 0.770 |
Why?
|
| Prosthesis Design | 6 | 2020 | 222 | 0.750 |
Why?
|
| Aspirin | 3 | 2020 | 172 | 0.740 |
Why?
|
| Contrast Media | 12 | 2024 | 432 | 0.730 |
Why?
|
| Image Enhancement | 3 | 2014 | 193 | 0.720 |
Why?
|
| Intracranial Arteriosclerosis | 6 | 2025 | 49 | 0.720 |
Why?
|
| Male | 67 | 2024 | 31208 | 0.710 |
Why?
|
| Aneurysm, Ruptured | 5 | 2024 | 82 | 0.700 |
Why?
|
| Cerebrovascular Circulation | 9 | 2022 | 183 | 0.690 |
Why?
|
| Enbucrilate | 4 | 2024 | 9 | 0.690 |
Why?
|
| Embolism | 1 | 2021 | 41 | 0.680 |
Why?
|
| Intracranial Arteriovenous Malformations | 6 | 2013 | 84 | 0.680 |
Why?
|
| Microcirculation | 3 | 2026 | 59 | 0.670 |
Why?
|
| Endothelium, Vascular | 3 | 2020 | 177 | 0.660 |
Why?
|
| Ethiodized Oil | 4 | 2024 | 7 | 0.640 |
Why?
|
| Diagnostic Imaging | 2 | 2021 | 272 | 0.640 |
Why?
|
| Proof of Concept Study | 2 | 2022 | 39 | 0.640 |
Why?
|
| Dependovirus | 9 | 2025 | 758 | 0.640 |
Why?
|
| Cerebral Arteries | 6 | 2024 | 41 | 0.640 |
Why?
|
| Genetic Therapy | 10 | 2025 | 849 | 0.640 |
Why?
|
| Cerebral Revascularization | 3 | 2019 | 30 | 0.600 |
Why?
|
| Cryotherapy | 1 | 2019 | 16 | 0.600 |
Why?
|
| Carotid Artery, Internal | 5 | 2023 | 69 | 0.600 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2020 | 235 | 0.590 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2026 | 188 | 0.580 |
Why?
|
| Tomography, X-Ray Computed | 10 | 2024 | 1659 | 0.580 |
Why?
|
| Female | 61 | 2024 | 34216 | 0.580 |
Why?
|
| Equipment Design | 11 | 2020 | 371 | 0.560 |
Why?
|
| Self Expandable Metallic Stents | 4 | 2020 | 33 | 0.550 |
Why?
|
| Tissue Plasminogen Activator | 6 | 2022 | 126 | 0.550 |
Why?
|
| Tay-Sachs Disease | 3 | 2025 | 55 | 0.530 |
Why?
|
| Algorithms | 5 | 2026 | 1050 | 0.530 |
Why?
|
| Lung Neoplasms | 1 | 2024 | 708 | 0.530 |
Why?
|
| Ischemia | 3 | 2015 | 203 | 0.530 |
Why?
|
| Neuronavigation | 2 | 2018 | 13 | 0.500 |
Why?
|
| Genetic Vectors | 9 | 2025 | 926 | 0.500 |
Why?
|
| Blood Platelets | 5 | 2022 | 108 | 0.490 |
Why?
|
| Aged | 39 | 2024 | 15062 | 0.490 |
Why?
|
| Intracranial Thrombosis | 4 | 2016 | 28 | 0.490 |
Why?
|
| Academies and Institutes | 1 | 2016 | 24 | 0.480 |
Why?
|
| Equipment Failure Analysis | 7 | 2015 | 79 | 0.480 |
Why?
|
| Industry | 1 | 2016 | 59 | 0.480 |
Why?
|
| Retrospective Studies | 28 | 2023 | 6939 | 0.480 |
Why?
|
| Artifacts | 4 | 2019 | 128 | 0.470 |
Why?
|
| Catheterization | 3 | 2018 | 111 | 0.470 |
Why?
|
| Radial Artery | 3 | 2021 | 55 | 0.470 |
Why?
|
| Vasculitis, Central Nervous System | 1 | 2015 | 8 | 0.460 |
Why?
|
| Tissue Scaffolds | 1 | 2016 | 91 | 0.460 |
Why?
|
| Hyperplasia | 3 | 2018 | 91 | 0.460 |
Why?
|
| Radiography | 8 | 2014 | 558 | 0.450 |
Why?
|
| Tissue Engineering | 1 | 2016 | 148 | 0.440 |
Why?
|
| Cerebral Infarction | 2 | 2022 | 85 | 0.440 |
Why?
|
| Middle Aged | 39 | 2024 | 18393 | 0.430 |
Why?
|
| Sheep | 9 | 2025 | 194 | 0.420 |
Why?
|
| Foreign Bodies | 2 | 2021 | 56 | 0.420 |
Why?
|
| Acetic Acid | 2 | 2005 | 10 | 0.410 |
Why?
|
| Blood Chemical Analysis | 1 | 2014 | 20 | 0.410 |
Why?
|
| Blood Vessel Prosthesis Implantation | 4 | 2016 | 277 | 0.400 |
Why?
|
| Image Processing, Computer-Assisted | 7 | 2020 | 699 | 0.390 |
Why?
|
| Biomedical Research | 1 | 2016 | 263 | 0.390 |
Why?
|
| Drug Delivery Systems | 3 | 2015 | 333 | 0.380 |
Why?
|
| Convection | 2 | 2013 | 10 | 0.380 |
Why?
|
| Arterial Occlusive Diseases | 4 | 2019 | 67 | 0.380 |
Why?
|
| Neuroimaging | 1 | 2014 | 165 | 0.380 |
Why?
|
| Alloys | 4 | 2023 | 30 | 0.380 |
Why?
|
| Biomimetic Materials | 2 | 2012 | 39 | 0.380 |
Why?
|
| Models, Cardiovascular | 2 | 2011 | 83 | 0.370 |
Why?
|
| Fibrinolytic Agents | 4 | 2025 | 183 | 0.370 |
Why?
|
| Coated Materials, Biocompatible | 2 | 2024 | 45 | 0.360 |
Why?
|
| Forelimb | 1 | 2011 | 11 | 0.350 |
Why?
|
| Brachial Artery | 1 | 2011 | 27 | 0.350 |
Why?
|
| Blood Volume | 1 | 2011 | 40 | 0.350 |
Why?
|
| Erythrocytes | 5 | 2021 | 146 | 0.340 |
Why?
|
| Phosphorylcholine | 2 | 2024 | 45 | 0.330 |
Why?
|
| Acute Disease | 5 | 2020 | 663 | 0.330 |
Why?
|
| Adult | 28 | 2019 | 17467 | 0.320 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 2 | 2008 | 76 | 0.320 |
Why?
|
| Subarachnoid Hemorrhage | 4 | 2015 | 110 | 0.310 |
Why?
|
| Neovascularization, Physiologic | 2 | 2008 | 113 | 0.310 |
Why?
|
| Neuroradiography | 1 | 2010 | 11 | 0.310 |
Why?
|
| Reproducibility of Results | 9 | 2022 | 1710 | 0.310 |
Why?
|
| Silicones | 2 | 2009 | 14 | 0.310 |
Why?
|
| Carotid Artery, Common | 5 | 2024 | 30 | 0.310 |
Why?
|
| Blood Vessels | 4 | 2016 | 63 | 0.310 |
Why?
|
| Aged, 80 and over | 17 | 2024 | 5650 | 0.290 |
Why?
|
| Aneurysm | 3 | 2020 | 58 | 0.290 |
Why?
|
| Vascular Remodeling | 2 | 2020 | 23 | 0.280 |
Why?
|
| Angioplasty | 3 | 2017 | 53 | 0.280 |
Why?
|
| Bioprosthesis | 1 | 2009 | 38 | 0.280 |
Why?
|
| Surface Properties | 3 | 2024 | 283 | 0.280 |
Why?
|
| Hindlimb | 1 | 2008 | 54 | 0.270 |
Why?
|
| Huntingtin Protein | 2 | 2019 | 147 | 0.270 |
Why?
|
| Combined Modality Therapy | 3 | 2020 | 372 | 0.260 |
Why?
|
| Follow-Up Studies | 14 | 2016 | 2495 | 0.260 |
Why?
|
| Thrombolytic Therapy | 3 | 2017 | 204 | 0.260 |
Why?
|
| Vascular Surgical Procedures | 1 | 2010 | 240 | 0.260 |
Why?
|
| Prostheses and Implants | 2 | 2019 | 71 | 0.260 |
Why?
|
| Oxygen | 2 | 2022 | 321 | 0.260 |
Why?
|
| Injections | 3 | 2021 | 84 | 0.250 |
Why?
|
| Hydrodynamics | 2 | 2026 | 43 | 0.250 |
Why?
|
| RNA, Small Interfering | 3 | 2021 | 982 | 0.250 |
Why?
|
| Fibrin | 5 | 2021 | 19 | 0.250 |
Why?
|
| Injections, Intra-Arterial | 2 | 2008 | 21 | 0.250 |
Why?
|
| Reflex, Trigeminocardiac | 2 | 2016 | 5 | 0.250 |
Why?
|
| Sensitivity and Specificity | 5 | 2014 | 1172 | 0.240 |
Why?
|
| Meningeal Arteries | 2 | 2016 | 12 | 0.240 |
Why?
|
| Carotid Artery Diseases | 3 | 2016 | 61 | 0.240 |
Why?
|
| Cerebrospinal Fluid | 1 | 2026 | 29 | 0.240 |
Why?
|
| Ear | 1 | 2005 | 9 | 0.230 |
Why?
|
| Hexosaminidase A | 1 | 2025 | 6 | 0.230 |
Why?
|
| beta-Hexosaminidase alpha Chain | 1 | 2025 | 20 | 0.230 |
Why?
|
| Lung | 2 | 2024 | 969 | 0.230 |
Why?
|
| Blood Flow Velocity | 4 | 2012 | 74 | 0.230 |
Why?
|
| Radiography, Interventional | 3 | 2017 | 83 | 0.220 |
Why?
|
| Random Allocation | 4 | 2020 | 200 | 0.220 |
Why?
|
| Green Fluorescent Proteins | 2 | 2024 | 372 | 0.220 |
Why?
|
| Models, Animal | 6 | 2019 | 242 | 0.220 |
Why?
|
| Cerebellopontine Angle | 1 | 2024 | 9 | 0.210 |
Why?
|
| Neurofibromin 1 | 1 | 2024 | 14 | 0.210 |
Why?
|
| Gadolinium DTPA | 3 | 2018 | 84 | 0.210 |
Why?
|
| Basilar Artery | 2 | 2024 | 34 | 0.210 |
Why?
|
| Central Nervous System | 3 | 2024 | 200 | 0.210 |
Why?
|
| Neurofibromatosis 1 | 1 | 2024 | 30 | 0.210 |
Why?
|
| Cisterna Magna | 2 | 2024 | 17 | 0.210 |
Why?
|
| Codon, Nonsense | 1 | 2024 | 62 | 0.200 |
Why?
|
| Computed Tomography Angiography | 2 | 2023 | 141 | 0.200 |
Why?
|
| Microscopy | 2 | 2024 | 99 | 0.200 |
Why?
|
| Nanoparticles | 3 | 2015 | 548 | 0.200 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2005 | 234 | 0.200 |
Why?
|
| Atherosclerosis | 3 | 2015 | 162 | 0.190 |
Why?
|
| Heparin | 1 | 2024 | 120 | 0.190 |
Why?
|
| Microsurgery | 2 | 2022 | 54 | 0.190 |
Why?
|
| Kyphoplasty | 2 | 2013 | 3 | 0.190 |
Why?
|
| Gadolinium | 2 | 2015 | 110 | 0.190 |
Why?
|
| Cerebral Veins | 1 | 2023 | 38 | 0.190 |
Why?
|
| Fractures, Compression | 2 | 2013 | 9 | 0.190 |
Why?
|
| Bone Cements | 2 | 2013 | 17 | 0.190 |
Why?
|
| Registries | 3 | 2024 | 931 | 0.190 |
Why?
|
| Radiosurgery | 2 | 2013 | 67 | 0.190 |
Why?
|
| Spinal Fractures | 2 | 2013 | 41 | 0.190 |
Why?
|
| Osteoporotic Fractures | 2 | 2013 | 36 | 0.190 |
Why?
|
| Intravital Microscopy | 1 | 2022 | 13 | 0.180 |
Why?
|
| Thalamus | 2 | 2020 | 77 | 0.180 |
Why?
|
| Infarction | 1 | 2022 | 20 | 0.180 |
Why?
|
| Carotid Artery, Internal, Dissection | 1 | 2022 | 19 | 0.180 |
Why?
|
| Young Adult | 7 | 2019 | 4839 | 0.180 |
Why?
|
| Vasospasm, Intracranial | 2 | 2014 | 30 | 0.180 |
Why?
|
| Pancreatic Elastase | 5 | 2020 | 32 | 0.170 |
Why?
|
| Gene Transfer Techniques | 2 | 2024 | 325 | 0.170 |
Why?
|
| Aneurysm, False | 1 | 2022 | 47 | 0.170 |
Why?
|
| Neurons | 2 | 2018 | 934 | 0.170 |
Why?
|
| Radiographic Image Enhancement | 3 | 2013 | 99 | 0.170 |
Why?
|
| Equipment Contamination | 1 | 2021 | 34 | 0.170 |
Why?
|
| Consensus | 2 | 2024 | 177 | 0.170 |
Why?
|
| Iatrogenic Disease | 1 | 2021 | 58 | 0.160 |
Why?
|
| Evaluation Studies as Topic | 1 | 2020 | 105 | 0.160 |
Why?
|
| Machine Learning | 2 | 2019 | 195 | 0.160 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 214 | 0.160 |
Why?
|
| Vertebral Artery | 1 | 2020 | 29 | 0.160 |
Why?
|
| Carotid Arteries | 1 | 2020 | 64 | 0.160 |
Why?
|
| Arteries | 1 | 2020 | 81 | 0.160 |
Why?
|
| Neointima | 2 | 2018 | 19 | 0.160 |
Why?
|
| Administration, Intravenous | 1 | 2020 | 76 | 0.150 |
Why?
|
| Orbit | 1 | 2019 | 18 | 0.150 |
Why?
|
| Muscle, Skeletal | 1 | 2005 | 787 | 0.150 |
Why?
|
| Cerebral Arterial Diseases | 1 | 2019 | 8 | 0.150 |
Why?
|
| High-Intensity Focused Ultrasound Ablation | 1 | 2019 | 5 | 0.150 |
Why?
|
| Hypothermia, Induced | 1 | 2019 | 40 | 0.150 |
Why?
|
| Meningeal Neoplasms | 2 | 2016 | 62 | 0.150 |
Why?
|
| Meningioma | 2 | 2016 | 64 | 0.150 |
Why?
|
| Gene Expression | 2 | 2019 | 854 | 0.150 |
Why?
|
| Vascular Malformations | 1 | 2019 | 22 | 0.140 |
Why?
|
| Cattle | 3 | 2019 | 320 | 0.140 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2019 | 165 | 0.140 |
Why?
|
| Particle Size | 2 | 2021 | 431 | 0.140 |
Why?
|
| Staining and Labeling | 1 | 2019 | 127 | 0.140 |
Why?
|
| DNA | 1 | 2023 | 852 | 0.140 |
Why?
|
| Caudate Nucleus | 1 | 2018 | 25 | 0.140 |
Why?
|
| Putamen | 1 | 2018 | 21 | 0.140 |
Why?
|
| Transduction, Genetic | 1 | 2019 | 242 | 0.130 |
Why?
|
| Microscopy, Electron, Scanning | 2 | 2019 | 111 | 0.130 |
Why?
|
| Subclavian Artery | 2 | 2011 | 26 | 0.130 |
Why?
|
| Feasibility Studies | 5 | 2017 | 589 | 0.130 |
Why?
|
| Time Factors | 6 | 2017 | 3774 | 0.130 |
Why?
|
| beta-N-Acetylhexosaminidases | 1 | 2017 | 19 | 0.130 |
Why?
|
| Dyskinesias | 1 | 2017 | 9 | 0.130 |
Why?
|
| Virus Internalization | 1 | 2018 | 91 | 0.130 |
Why?
|
| Posterior Cerebral Artery | 1 | 2016 | 13 | 0.130 |
Why?
|
| Sus scrofa | 2 | 2019 | 30 | 0.130 |
Why?
|
| Vertebrobasilar Insufficiency | 1 | 2017 | 27 | 0.130 |
Why?
|
| Gangliosidoses, GM2 | 1 | 2017 | 18 | 0.120 |
Why?
|
| Biosensing Techniques | 1 | 2018 | 126 | 0.120 |
Why?
|
| Secondary Prevention | 1 | 2017 | 165 | 0.120 |
Why?
|
| Tellurium | 1 | 2016 | 5 | 0.120 |
Why?
|
| Photons | 1 | 2016 | 23 | 0.120 |
Why?
|
| Necrosis | 1 | 2017 | 148 | 0.120 |
Why?
|
| Cadmium Compounds | 1 | 2016 | 25 | 0.120 |
Why?
|
| Bradycardia | 1 | 2016 | 33 | 0.120 |
Why?
|
| Therapy, Computer-Assisted | 1 | 2016 | 23 | 0.120 |
Why?
|
| Fluoroscopy | 2 | 2017 | 69 | 0.120 |
Why?
|
| Software | 1 | 2019 | 401 | 0.120 |
Why?
|
| Radiometry | 1 | 2016 | 39 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 808 | 0.120 |
Why?
|
| Surgery, Computer-Assisted | 3 | 2019 | 56 | 0.120 |
Why?
|
| Lipopeptides | 1 | 2015 | 15 | 0.120 |
Why?
|
| Robotic Surgical Procedures | 1 | 2019 | 172 | 0.120 |
Why?
|
| Shear Strength | 1 | 2015 | 19 | 0.120 |
Why?
|
| Echoencephalography | 1 | 2015 | 14 | 0.120 |
Why?
|
| Species Specificity | 2 | 2011 | 340 | 0.110 |
Why?
|
| Vertebral Artery Dissection | 1 | 2015 | 22 | 0.110 |
Why?
|
| Helium | 1 | 2015 | 7 | 0.110 |
Why?
|
| Prosthesis Failure | 1 | 2015 | 78 | 0.110 |
Why?
|
| Regional Blood Flow | 3 | 2005 | 116 | 0.110 |
Why?
|
| Alzheimer Disease | 1 | 2022 | 766 | 0.110 |
Why?
|
| Dimethyl Sulfoxide | 1 | 2015 | 15 | 0.110 |
Why?
|
| Apolipoproteins E | 1 | 2015 | 115 | 0.110 |
Why?
|
| Polyvinyls | 1 | 2015 | 19 | 0.110 |
Why?
|
| Interprofessional Relations | 1 | 2016 | 137 | 0.110 |
Why?
|
| Molecular Imaging | 1 | 2015 | 52 | 0.110 |
Why?
|
| Models, Statistical | 2 | 2014 | 309 | 0.110 |
Why?
|
| Disease Progression | 1 | 2019 | 1224 | 0.110 |
Why?
|
| Dantrolene | 1 | 2014 | 8 | 0.110 |
Why?
|
| Muscle Relaxants, Central | 1 | 2014 | 12 | 0.110 |
Why?
|
| Pulmonary Artery | 1 | 2015 | 96 | 0.110 |
Why?
|
| Cooperative Behavior | 1 | 2016 | 230 | 0.110 |
Why?
|
| Blood Pressure | 2 | 2008 | 535 | 0.110 |
Why?
|
| Cerebellum | 1 | 2015 | 94 | 0.110 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2014 | 61 | 0.110 |
Why?
|
| Permeability | 1 | 2014 | 51 | 0.110 |
Why?
|
| Motion | 1 | 2014 | 65 | 0.100 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 231 | 0.100 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2017 | 228 | 0.100 |
Why?
|
| Radiology, Interventional | 1 | 2014 | 31 | 0.100 |
Why?
|
| Vertebroplasty | 1 | 2013 | 8 | 0.100 |
Why?
|
| Risk Factors | 4 | 2019 | 5462 | 0.100 |
Why?
|
| Reperfusion | 2 | 2016 | 37 | 0.100 |
Why?
|
| Nanotechnology | 1 | 2015 | 139 | 0.100 |
Why?
|
| Polymers | 3 | 2005 | 331 | 0.100 |
Why?
|
| Lung Diseases | 1 | 2015 | 183 | 0.100 |
Why?
|
| X-Ray Intensifying Screens | 1 | 2013 | 8 | 0.100 |
Why?
|
| Elasticity | 2 | 2011 | 45 | 0.100 |
Why?
|
| Device Approval | 1 | 2013 | 13 | 0.100 |
Why?
|
| Risk | 1 | 2014 | 374 | 0.100 |
Why?
|
| Pilot Projects | 2 | 2014 | 1021 | 0.090 |
Why?
|
| United States Food and Drug Administration | 1 | 2013 | 92 | 0.090 |
Why?
|
| Safety | 1 | 2013 | 142 | 0.090 |
Why?
|
| Anticoagulants | 1 | 2017 | 529 | 0.090 |
Why?
|
| Pulmonary Embolism | 1 | 2015 | 196 | 0.090 |
Why?
|
| Gene Expression Regulation | 1 | 2019 | 1632 | 0.090 |
Why?
|
| Corpus Striatum | 1 | 2013 | 98 | 0.090 |
Why?
|
| Chronic Disease | 2 | 2005 | 742 | 0.090 |
Why?
|
| Thoracic Vertebrae | 1 | 2012 | 35 | 0.090 |
Why?
|
| Databases, Factual | 1 | 2015 | 887 | 0.090 |
Why?
|
| Prosthesis Implantation | 1 | 2012 | 30 | 0.090 |
Why?
|
| Rats | 4 | 2019 | 1996 | 0.090 |
Why?
|
| Eating | 2 | 2022 | 140 | 0.090 |
Why?
|
| Barium Sulfate | 1 | 2011 | 17 | 0.090 |
Why?
|
| Thrombin | 1 | 2011 | 21 | 0.090 |
Why?
|
| Blood-Brain Barrier | 1 | 2011 | 87 | 0.080 |
Why?
|
| Huntington Disease | 1 | 2013 | 160 | 0.080 |
Why?
|
| Stress, Mechanical | 1 | 2011 | 117 | 0.080 |
Why?
|
| Carotid Stenosis | 2 | 2010 | 100 | 0.080 |
Why?
|
| Iopamidol | 1 | 2010 | 13 | 0.080 |
Why?
|
| Biophysics | 2 | 2019 | 42 | 0.080 |
Why?
|
| X-Rays | 3 | 2017 | 47 | 0.080 |
Why?
|
| Adolescent | 4 | 2018 | 6333 | 0.080 |
Why?
|
| Lumbar Vertebrae | 1 | 2012 | 178 | 0.080 |
Why?
|
| NADPH Oxidases | 1 | 2010 | 69 | 0.080 |
Why?
|
| Macrophages | 1 | 2015 | 1038 | 0.080 |
Why?
|
| Prospective Studies | 4 | 2020 | 3326 | 0.070 |
Why?
|
| Endarterectomy, Carotid | 1 | 2010 | 79 | 0.070 |
Why?
|
| Nicardipine | 1 | 2008 | 3 | 0.070 |
Why?
|
| Atrial Fibrillation | 1 | 2017 | 884 | 0.070 |
Why?
|
| Biomarkers | 1 | 2014 | 1484 | 0.070 |
Why?
|
| Inflammation | 3 | 2023 | 1194 | 0.070 |
Why?
|
| Rats, Wistar | 2 | 2019 | 184 | 0.070 |
Why?
|
| Transgenes | 2 | 2019 | 207 | 0.060 |
Why?
|
| Membrane Glycoproteins | 1 | 2010 | 662 | 0.060 |
Why?
|
| Nervous System Diseases | 1 | 2008 | 108 | 0.060 |
Why?
|
| Infant | 1 | 2011 | 1704 | 0.060 |
Why?
|
| Massachusetts | 1 | 2012 | 2153 | 0.060 |
Why?
|
| Sheep, Domestic | 2 | 2018 | 13 | 0.060 |
Why?
|
| beta-Hexosaminidase beta Chain | 1 | 2025 | 8 | 0.060 |
Why?
|
| G(M2) Ganglioside | 1 | 2025 | 15 | 0.060 |
Why?
|
| Iodized Oil | 1 | 2005 | 2 | 0.060 |
Why?
|
| Stereotaxic Techniques | 2 | 2018 | 30 | 0.060 |
Why?
|
| Brachiocephalic Trunk | 1 | 2005 | 15 | 0.060 |
Why?
|
| Viscosity | 1 | 2005 | 60 | 0.060 |
Why?
|
| Drug Combinations | 1 | 2005 | 166 | 0.060 |
Why?
|
| Adenoviridae | 1 | 2005 | 130 | 0.050 |
Why?
|
| Animals, Genetically Modified | 2 | 2018 | 312 | 0.050 |
Why?
|
| Oxadiazoles | 1 | 2024 | 8 | 0.050 |
Why?
|
| Miniaturization | 1 | 2024 | 10 | 0.050 |
Why?
|
| Tissue Distribution | 1 | 2024 | 293 | 0.050 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2005 | 465 | 0.050 |
Why?
|
| Kinetics | 1 | 2005 | 757 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 857 | 0.050 |
Why?
|
| Drug-Eluting Stents | 1 | 2024 | 68 | 0.050 |
Why?
|
| Disease Management | 1 | 2025 | 235 | 0.050 |
Why?
|
| Organometallic Compounds | 1 | 2023 | 71 | 0.050 |
Why?
|
| Wound Healing | 1 | 2024 | 193 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2023 | 113 | 0.050 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2022 | 28 | 0.050 |
Why?
|
| Simvastatin | 1 | 2022 | 26 | 0.050 |
Why?
|
| Oxidation-Reduction | 1 | 2023 | 328 | 0.050 |
Why?
|
| Iron | 1 | 2023 | 155 | 0.050 |
Why?
|
| von Willebrand Factor | 1 | 2022 | 10 | 0.050 |
Why?
|
| Osmolar Concentration | 1 | 2002 | 91 | 0.050 |
Why?
|
| Drug Administration Routes | 1 | 2021 | 22 | 0.040 |
Why?
|
| Biophysical Phenomena | 1 | 2002 | 23 | 0.040 |
Why?
|
| Recurrence | 2 | 2016 | 662 | 0.040 |
Why?
|
| Arginine | 1 | 2022 | 136 | 0.040 |
Why?
|
| United States | 2 | 2013 | 8149 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2015 | 624 | 0.040 |
Why?
|
| Femoral Artery | 1 | 2002 | 104 | 0.040 |
Why?
|
| Anticonvulsants | 1 | 2022 | 104 | 0.040 |
Why?
|
| Mice | 3 | 2024 | 11145 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2024 | 1290 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2005 | 1039 | 0.040 |
Why?
|
| Neuropsychological Tests | 1 | 2022 | 412 | 0.040 |
Why?
|
| Longitudinal Studies | 2 | 2015 | 1285 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2019 | 2633 | 0.040 |
Why?
|
| Cadaver | 1 | 2020 | 135 | 0.040 |
Why?
|
| Postoperative Complications | 3 | 2015 | 1334 | 0.040 |
Why?
|
| Apoptosis | 1 | 2005 | 1098 | 0.040 |
Why?
|
| Injections, Spinal | 1 | 2019 | 44 | 0.040 |
Why?
|
| Clot Retraction | 1 | 2019 | 3 | 0.040 |
Why?
|
| Blood Cell Count | 1 | 2019 | 33 | 0.040 |
Why?
|
| Coronary Thrombosis | 1 | 2019 | 21 | 0.040 |
Why?
|
| Endothelial Cells | 1 | 2021 | 213 | 0.040 |
Why?
|
| Platelet Adhesiveness | 1 | 2019 | 7 | 0.040 |
Why?
|
| Platelet Aggregation | 1 | 2019 | 24 | 0.040 |
Why?
|
| Health Care Sector | 1 | 2009 | 20 | 0.040 |
Why?
|
| Video Recording | 1 | 2019 | 140 | 0.040 |
Why?
|
| Genes, Reporter | 1 | 2019 | 257 | 0.040 |
Why?
|
| Workflow | 1 | 2019 | 77 | 0.040 |
Why?
|
| Platinum | 2 | 2009 | 20 | 0.040 |
Why?
|
| Mice, Nude | 1 | 2019 | 287 | 0.030 |
Why?
|
| Cognition | 1 | 2022 | 510 | 0.030 |
Why?
|
| Forecasting | 1 | 2019 | 230 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 223 | 0.030 |
Why?
|
| Wool | 1 | 2018 | 5 | 0.030 |
Why?
|
| Atlases as Topic | 1 | 2018 | 14 | 0.030 |
Why?
|
| Internal Capsule | 1 | 2018 | 11 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2009 | 158 | 0.030 |
Why?
|
| Neostriatum | 1 | 2018 | 26 | 0.030 |
Why?
|
| Serogroup | 1 | 2018 | 35 | 0.030 |
Why?
|
| Corpus Callosum | 1 | 2018 | 42 | 0.030 |
Why?
|
| Extracellular Matrix | 1 | 2019 | 148 | 0.030 |
Why?
|
| Phosphorus | 1 | 2017 | 16 | 0.030 |
Why?
|
| Choline | 1 | 2017 | 23 | 0.030 |
Why?
|
| Research | 1 | 2009 | 195 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 1115 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2019 | 868 | 0.030 |
Why?
|
| Coronary Vessels | 1 | 2018 | 125 | 0.030 |
Why?
|
| Injections, Intraventricular | 1 | 2017 | 23 | 0.030 |
Why?
|
| Macaca fascicularis | 1 | 2017 | 48 | 0.030 |
Why?
|
| Apathy | 1 | 2017 | 9 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2024 | 3489 | 0.030 |
Why?
|
| Aorta, Abdominal | 1 | 2017 | 56 | 0.030 |
Why?
|
| Radiation Exposure | 1 | 2017 | 25 | 0.030 |
Why?
|
| Genome, Viral | 1 | 2018 | 145 | 0.030 |
Why?
|
| Gray Matter | 1 | 2017 | 39 | 0.030 |
Why?
|
| Iohexol | 1 | 2016 | 18 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 2019 | 431 | 0.030 |
Why?
|
| Protein Subunits | 1 | 2017 | 169 | 0.030 |
Why?
|
| Polymethyl Methacrylate | 1 | 2016 | 15 | 0.030 |
Why?
|
| Wrist | 1 | 2016 | 39 | 0.030 |
Why?
|
| Suction | 1 | 2016 | 33 | 0.030 |
Why?
|
| Finite Element Analysis | 1 | 2015 | 13 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2017 | 140 | 0.030 |
Why?
|
| Fingers | 1 | 2016 | 49 | 0.030 |
Why?
|
| Lipoproteins, HDL | 1 | 2015 | 35 | 0.030 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2015 | 34 | 0.030 |
Why?
|
| White Matter | 1 | 2017 | 128 | 0.030 |
Why?
|
| Fluorescence | 1 | 2015 | 93 | 0.030 |
Why?
|
| Linear Models | 1 | 2016 | 405 | 0.030 |
Why?
|
| Syncope | 1 | 2015 | 42 | 0.030 |
Why?
|
| Aorta | 1 | 2015 | 108 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2015 | 240 | 0.030 |
Why?
|
| Age Factors | 1 | 2019 | 1592 | 0.030 |
Why?
|
| Headache | 1 | 2015 | 58 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2019 | 1568 | 0.030 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2018 | 226 | 0.030 |
Why?
|
| Cytoplasm | 1 | 2015 | 283 | 0.030 |
Why?
|
| Brain Mapping | 1 | 2015 | 240 | 0.030 |
Why?
|
| Drug Design | 1 | 2015 | 137 | 0.030 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 2013 | 16 | 0.030 |
Why?
|
| Arteriovenous Malformations | 1 | 2014 | 45 | 0.030 |
Why?
|
| Patient Selection | 1 | 2016 | 484 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2019 | 1577 | 0.020 |
Why?
|
| Spine | 1 | 2013 | 55 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2014 | 744 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2015 | 1143 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2013 | 199 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2012 | 208 | 0.020 |
Why?
|
| Cell Line | 1 | 2015 | 2024 | 0.020 |
Why?
|
| Mutation | 1 | 2019 | 2666 | 0.020 |
Why?
|
| Fluorescein Angiography | 1 | 2011 | 63 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2015 | 2162 | 0.020 |
Why?
|
| NADPH Oxidase 2 | 1 | 2010 | 36 | 0.020 |
Why?
|
| Normal Distribution | 1 | 2010 | 17 | 0.020 |
Why?
|
| Fourier Analysis | 1 | 2010 | 31 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2011 | 491 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2010 | 149 | 0.020 |
Why?
|
| Ticlopidine | 1 | 2009 | 47 | 0.020 |
Why?
|
| Intracranial Pressure | 1 | 2008 | 19 | 0.020 |
Why?
|
| Calcium Channel Blockers | 1 | 2008 | 58 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 213 | 0.020 |
Why?
|
| Body Weight | 1 | 2008 | 376 | 0.020 |
Why?
|
| Mathematics | 1 | 2006 | 34 | 0.020 |
Why?
|
| Prognosis | 1 | 2010 | 1789 | 0.010 |
Why?
|
| Electromagnetic Fields | 1 | 2005 | 15 | 0.010 |
Why?
|
| Elastomers | 1 | 2005 | 7 | 0.010 |
Why?
|
| Hot Temperature | 1 | 2005 | 147 | 0.010 |
Why?
|
| Biomedical Engineering | 1 | 2001 | 8 | 0.010 |
Why?
|
| Balloon Occlusion | 1 | 2000 | 11 | 0.010 |
Why?
|
| Child | 1 | 2007 | 4623 | 0.010 |
Why?
|